Insider Transactions in Q2 2025 at Verve Therapeutics, Inc. (VERV)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 02
2025
|
Troy Lister Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,189
-23.95%
|
$8,756
$4.15 P/Share
|
|
Apr 02
2025
|
Allison Dorval Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,350
-20.14%
|
$13,400
$4.15 P/Share
|
|
Apr 02
2025
|
Jason Politi Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
3,235
-18.53%
|
$12,940
$4.15 P/Share
|
|
Apr 02
2025
|
Andrew D. Ashe |
SELL
Open market or private sale
|
Direct |
2,681
-0.76%
|
$10,724
$4.15 P/Share
|
|
Apr 02
2025
|
Joan Nickerson Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
2,777
-13.75%
|
$11,108
$4.15 P/Share
|
|
Apr 02
2025
|
Sekar Kathiresan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,822
-2.76%
|
$39,288
$4.15 P/Share
|
|
Apr 01
2025
|
Troy Lister Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,340
+44.54%
|
-
|
|
Apr 01
2025
|
Allison Dorval Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+40.35%
|
-
|
|
Apr 01
2025
|
Jason Politi Chief Technical Ops. Off. |
BUY
Exercise of conversion of derivative security
|
Direct |
8,815
+33.55%
|
-
|
|
Apr 01
2025
|
Andrew D. Ashe |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+2.5%
|
-
|
|
Apr 01
2025
|
Joan Nickerson Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,315
+31.56%
|
-
|
|
Apr 01
2025
|
Sekar Kathiresan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,000
+8.47%
|
-
|